Drug intelligence / Profile preview

allogenic adipose-derived mesenchymal stem cells + autologous bone marrow mononuclear cells

Development stage
Unknown
Lead developer
Sophia Al-Adwan
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

This experimental cell therapy combination is being evaluated for the treatment of newly diagnosed Type 1 Diabetes Mellitus (T1DM). It involves the administration of allogenic adipose-derived mesenchymal stem cells (AD-MSCs) in conjunction with autologous bone marrow mononuclear cells (BMMCs). AD-MSCs are utilized for their potent immunomodulatory and anti-inflammatory properties, which aim to halt the autoimmune destruction of insulin-producing beta cells. BMMCs, which contain a heterogeneous population of progenitor cells, are included to potentially support revascularization and the regeneration of the pancreatic microenvironment. The primary goal of this Phase I study, led by Sophia Al-Adwan, is to assess the safety and feasibility of this combined cellular approach in adult patients.

Other names
Adipose mesenchymal cells with bone marrow mononuclear cellsAD-MSC + BMMC

Beyond the preview

Go deeper on allogenic adipose-derived mesenchymal stem cells + autologous bone marrow mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogenic adipose-derived mesenchymal stem cells + autologous bone marrow mononuclear cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call